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Background: Preventive pharmacotherapy for migraine is not satisfactory because of the low efficacy/tolerability
ratio of many available drugs. Novel and more efficient preventive strategies are therefore warranted. Abnormal
excitability of cortical areas appears to play a pivotal role in migraine pathophysiology. Transcranial direct current
stimulation (tDCS) is a non-invasive and safe technique that is able to durably modulate the activity of the
underlying cerebral cortex, and is being tested in various medical indications. The results of small open studies
using tDCS in migraine prophylaxis are conflicting, possibly because the optimal stimulation settings and the brain
targets were not well chosen. We have previously shown that the cerebral cortex, especially the visual cortex, is
hyperresponsive in migraine patients between attacks and provided evidence from evoked potential studies that
this is due to a decreased cortical preactivation level. If one accepts this concept, anodal tDCS over the visual
cortex may have therapeutic potentials in migraine prevention, as it is able to increase neuronal firing.
Objective: To study the effects of anodal tDCS on visual cortex activity in healthy volunteers (HV) and episodic
migraine without aura patients (MoA), and its potentials for migraine prevention.
Methods: We recorded pattern-reversal visual evoked potentials (VEP) before and after a 15-min session of anodal
tDCS over the visual cortex in 11 HV and 13 MoA interictally. Then 10 MoA patients reporting at least 4 attacks/
month subsequently participated in a therapeutic study, and received 2 similar sessions of tDCS per week for 8
weeks as migraine preventive therapy.
Results: In HV as well as in MoA, anodal tDCS transiently increased habituation of the VEP N1P1 component. VEP
amplitudes were not modified by tDCS. Preventive treatment with anodal tDCS turned out to be beneficial in MoA:
migraine attack frequency, migraine days, attack duration and acute medication intake significantly decreased
during the treatment period compared to pre-treatment baseline (all p < 0.05), and this benefit persisted on
average 4.8 weeks after the end of tDCS.
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Conclusions: Anodal tDCS over the visual cortex is thus able to increase habituation to repetitive visual stimuli in
healthy volunteers and in episodic migraineurs, who on average lack habituation interictally. Moreover, 2 weekly
sessions of anodal tDCS had a significant preventive anti- migraine effect, proofing the concept that the low
preactivation level of the visual cortex in migraine patients can be corrected by an activating neurostimulation.
The therapeutic results indicate that a larger sham-controlled trial using the same tDCS protocol is worthwhile.
Keywords: Migraine, Habituation deficit, tDCS, Treatment, Visual cortexBackground
Finding the ‘right’ migraine preventive treatment often
remains a challenge in many patients. The drugs currently
used in migraine prophylaxis (such as antiepileptics, beta
blockers. . .) are not migraine-specific, unlike acute thera-
pies like triptans or gepans, which were designed to treat
headache. Moreover, they are not devoid of side-effects
and their efficacy rarely exceeds 50-60% for the best of
them [1]. Chronic migraine patients, i.e. the presence of at
least 15 days of headache per month, of which at least 8
migraine attacks, represent almost the 2-3% of the popula-
tion and they are particularly difficult to manage as their
response to existing preventive therapies is often unsatis-
factory [2,3]. There is thus a need for new effective and
well-tolerated treatments in migraine prophylaxis. The
latter should ideally be more disease-specific, i.e. designed
to counteract the dysfunctions known to be involved in
migraine pathogenesis.
Migraine is a complex and heterogeneous disorder, in
which genetics and environment interact to generate
dysfunctioning paths and loops at several levels of the
central nervous system. These intricate phenomena are
responsible for the multifaceted clinical features of the
disease and especially its dynamics characterized by a cyclic
ictal-interictal pattern and the repetition of attacks [4].
It has been known for a long time that the brain excit-
ability is abnormal in migraine during the interictal
period [5]. However many past studies on cortical excit-
ability had provided conflicting results, and whether the
brain was hyperexcitable [6-8] or hypoexcitable [9-12]
remained extensively debated for years. A recent theory
proposed a semantic modification that was able to unify
these opposite hypotheses, i.e. that the brain cortex was
not hyperexcitable per se but hyperresponsive to sensory
stimuli in migraine between attacks [13]. A reproducible
hallmark mirroring this hyperresponsiveness is the lack
of habituation to repeated sensory or cognitive stimu-
lations reported in both evoked potentials and neuroi-
maging trials (for review, see [14]). Habituation is defined
as a behavioural response decrement that results from
repeated stimulations and does not involve sensory
adaptation or fatigue, i.e. a decrease in peripheral receptor
activity [15]. According to Groves and Thompson, habitu-
ation relies on the balance of two opposite mechanisms,facilitation and depression of brain responses to a sensory
stimulus.
In the interictal period of migraine, many evoked poten-
tials studies to various sensory modalities found on average
lower initial response amplitudes followed by a decreased
habituation -or even a potentiation- of subsequent re-
sponses, whereas in healthy subjects a higher initial re-
sponse preceded a more pronounced habituation. These
results paved the way to the hypothesis that the lack of ha-
bituation was possibly due to a lower preactivation level of
brain sensory cortices, according to the ceiling theory [16].
Recent studies suggested that this lower preactivation
level could be the consequence of impaired functional
thalamocortical loops, the so-called Thalamocortical Dys-
rhythmia, a dysfunction, which is also involved in other
neurological diseases [17,18]. Further works demonstrated
that the lack of habituation was not constant and normal-
ized just before and during the migraine attack. Interest-
ingly, it was recently shown that in chronic migraine
patients habituation was normal [19] but evolved to po-
tentiation when these chronic migraineurs went to re-
mission towards episodic migraine [20], suggesting that
chronic migraine could be considered as a “never-ending
attack” [21].
In the last decade there has been an increasing interest
for neuromodulation in migraine treatment [22]. Even if
randomized controlled trials are scarce, some preliminary
results are encouraging and peripheral and central
neuromodulating techniques are considered as promising
alternatives to pharmacological treatment. Among them, 2
central non-invasive techniques appear particularly suit-
able for migraine preventive treatment: repetitive transcra-
nial magnetic stimulation (rTMS) and trancranial Direct
Current Stimulation (tDCS). Both are able to durably
modify the excitability of the underlying cortex and could
potentially correct the functional abnormalities found in
migraine patients. They were already applied in several
other neurological diseases with some success [23]. High
frequency (around 10 Hz) rTMS stimulation can increase
brain excitability, while low frequency rTMS (about 1 Hz)
is able to decrease it [23,24]. Anodal tDCS appears to
increase brain excitability, while cathodal tDCS stimula-
tion decreases it [23,25-27] though not all studies agreed
on this point [28].
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migraine prevention, and their results were conflicting
[29-31]. This could be due to dissimilarities in their stimu-
lation protocols, as stimulated brain regions as well as
stimulation frequencies, length and intensities were diffe-
rent and depended on the baseline pathophysiological
hypothesis, mainly the belief that the migrainous brain was
hyperexcitable or, on the contrary, hypoexcitable. More-
over, these trials did not assess the brain excitability before
and after treatment. In a previous study, we had reported
that a single 10 Hz excitatory rTMS session was able to
restore normal habituation and initial amplitude of visual-
evoked responses (VEPs) in migraineurs, and that this
effect lasted at least 9 minutes. In a subsequent trial, this
stimulation was applied on 5 successive days, but the VEPs
normalization did not exceed several hours in most
migraineurs. However, these results had not been applied
in a preventative therapeutic study for now, and
whether the normalization of habituation was associated
to a clinical improvement remained unknown [12,32].
We therefore performed a pilot proof-of-concept study
combining the two approaches for the first time, but
we used anodal (i.e. excitatory) tDCS instead of 10 Hz-
rTMS. This was a 2-step trial: we first repeated the
electrophysiological study in healthy volunteers and
migraineurs in order to ensure that anodal tDCS could
modulate habituation and correct the impaired interictal
excitability in migraineurs like rTMS, then in the second
phase the same stimulation paradigm was converted into
a preventive therapy for episodic migraine in a prospective
pilot trial.
Methods
1. Subjects and clinical records
Eleven healthy volunteers (HV) were enrolled for the
electrophysiological study (5 males and 6 females, mean
age 25.8 ± SD 5.7 years). Exclusion criteria were: age below
18 or above 65 years, a personal history of recurrent head-
ache or other neurological diseases especially seizures,
familial history of recurrent headache, child migraine
equivalents (motion sickness, cyclic vomiting or recurrent
abdominal pain, somnambulism etc.. . .), chronic pain
syndromes, analgesics intake at the time of recording, and
contra-indications to tDCS neurostimulation (metal pros-
thetics in the head or internal stimulation like a pace-
maker). They were compared to 13 migraineurs without
aura (MoA) according to the second International Classifi-
cation of Headache Disorders (ICHD-IIR) criteria (2 males
and 11 females, mean age 29.3 ± 5.1). Patients had more
than 2 and less than 8 attacks/month and were not under
preventive therapy for at least 3 months before the experi-
mental day. All volunteers and patients were naive to anykind of neurostimulation, i.e. they never got this type of
treatment before (central or peripheral neurostimulation),
whatever the indication was. Patients were recruited
in the outpatient clinic through headache-specialized
consultations (DM and JS).
The therapeutic study involved 10 migraineurs suffering
from episodic MoA (2 males and 8 females, mean age
38.4 ± 16.3) with a frequency ranging between 3 and 8
attacks/month, knowing that none of them fulfilled the cri-
teria for chronic migraine. Only two of them were previ-
ously involved in the electrophysiological study. Intake of a
drug preventive treatment was allowed in the therapeutic
study only, but this pharmacological therapy had to be
stable for at least 2 months. Five out of the 10 enrolled pa-
tients were under preventive therapy at the moment of the
trial: one was taking riboflavin alone, two riboflavin associ-
ated with a beta-blocker (metoprolol or propranolol), the
other two were under topiramate. All of them had treat-
ment for several months and this treatment did not give
them any satisfaction. The average time under prophylactic
therapy at inclusion was 3.2 months (2 patients were under
preventive therapy for 2 months, the other 3 for 4 months).
During the whole therapeutic study period the patients
were asked to fill a headache diary to record migraine
attacks, migraine and headache days, pain intensity in a
scale from 1 (light) to 3 (severe), duration of attack (hours),
medication intake, and associated symptoms (nausea,
vomiting, photo- and phonophobia). This headache
diary had to be completed at least 2 months before
the treatment initiation, in order to have a 2-month
pretreatment baseline.
All subjects participating in the electrophysiological
and/or the therapeutic studies received detailed oral
and written explanations of the whole experiment
provided by the experimenter (AV or TSD) and gave
written informed consent. This study was approved
by the local Ethics Committee of the CHR Citadelle
Hospital of Liège, Belgium.
2. Material and stimulation protocols
Electrophysiological study
For the electrophysiological study we recorder pattern
reversal visual evoked potentials (PR-VEPs), as described
before [33]. PR-VEPs were selected as they are one of
the best studied electrophysiological responses in migraine,
where a decreased preactivation level and a lack of habitu-
ation has been reported in many studies [34]. Briefly,
subjects sat in a comfortable armchair in a quite dark room
at a +/− 90 cm distance from the monitor. They were
asked to relax and to fix a red sticker in the centre of the
screen (Nicolet™; 24 × 18 cm) with their right eye, the left
eye being covered by a patch. The visual stimulus was a
checkerboard pattern of black and white squares (15 mm
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temperature 9500 K) alternating at a frequency of 3.1 Hz.
Pin-electrodes were used to record the signal: the active
electrode was inserted at Oz and was referenced to Fz
according to the 10–20 system [34]. The ground electrode
was fixed to the right forearm. During uninterrupted
stimulation, 600 cortical responses were recorded
(CED™ 1902 preamplifier and CED™Micro1401 converter;
Cambridge Electronic Design Ltd, Cambridge, UK). Two
hundred and fifty milliseconds of the poststimulus period
were sampled at a rate of 4000 Hz.
Acquisitions were made at baseline (T0), immediately
after (T1) and 3 hours after (T2) a single anodal tDCS
session (see below). At the end of the first VEPs recording
(T0), the place of the pin electrodes was marked with a
pen, in order to ensure that their locations remained the
same in the subsequent recordings (T1 and T2). Hence,
after T1 the subjects had a 3-hour free time before coming
back to the laboratory for T2 acquisition. During this
period, they were not allowed to smoke, to drink alcohol
or beverages containing caffeine or other energy drinks,
and to take a nap. All recordings were distant from at least
72 hours of a migraine attack. The time of the last attack
was checked on patient’s diary and the absence of an
attack occurrence within the next 72 hours after the
experiment was checked by phone call. To avoid changes
of cortical excitability due to hormonal variations, all
female subjects performed the experiment in the first half










Figure 1 The time-dependent changes of N1P1 and P1N2
components of visual evoked potentials in a healthy subject.
Over six blocks of 100 averaged single trial responses a reduction in
amplitude of both components is shown, in the representative example.Anodal tDCS
Anodal tDCS stimulation was performed using a program-
mable DC stimulator (NeuroConn, Ilmeanu, Germany©)
with 2 rubber electrodes (5x7cm). The anode was placed in
the occipital region near Oz in order to stimulate the
underlying visual cortex, and the cathode was fixed
on the chin. We chose to put the cathode outside
the cranial vault in order to avoid a concomitant
inhibition of other cerebral cortices, for example the
frontal cortex when Fz had been chosen as cathode.
The subjects were stimulated at 1 mA intensity and
each session lasted 15 minutes. To decrease their
possible discomfort the stimulation increased gradually
during the first 8 seconds and decreased progressively
within the last 8 seconds of the tDCS.
Thus, the electrophysiological study comprised a
single tDCS session and in the therapeutic pilot
study anodal tDCS was applied twice a week for 8 weeks,
i.e. 16 sessions, using the same tDCS parameters.
The 2 weekly sessions were fixed, i.e. were always
applied the same days during the whole treatment
period of a single patient (for example, every Tuesday
and Friday).3. Data analysis and statistics.
In the electrophysiological study, the 600 PR-VEP
responses were averaged off-line into six blocks of 100
responses using Signal™ software version 4 (Cambridge
Electronic Design Ltd, bandpass 1–100 Hz). The peak-to
-peak N1–P1 and P1-N2 amplitudes were measured, N1
being the most negative point around 70 ms latency after
the stimulus (range 60–90), P1 the most positive around
100 ms latency (range 80–130) and N2 the most negative
point following P1 between 90 and 200 ms. To visualize
better the slope of N1P1 and P1N2 amplitude changes over
the total duration of visual stimulation, a linear regression
analysis of the mean amplitudes in the 6 blocks of 100
averages responses was performed and considered as the
reflect of habituation degree (see Figure 1). Hence, a
normal habituation gave a negative slope value, while
potentiation gave a positive slope. We calculated means
and standard deviations for the first block amplitude (first
100 averaged N1P1 VEP responses, ìV, which reflects
cortical preactivation level – see above introduction) and
N1P1 and P1N2 habituation slopes, at T0, T1 and T2, and
compared them between HV and MoA.
In the therapeutic study we followed prospectively the
evolution of migraine attack frequency, migraine days,
mean pain intensity, attack duration and acute drugs intake
during treatment with tDCS, compared to the baseline.
We compared baseline clinical variables (2nd month) with
those of the 2nd month of tDCS treatment, to study the
cumulative effect of the repeated stimulation.
Statistical calculations were carried out using
STATISTICA (version 7, StatSoft, Oklahoma, USA).
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tion of the variables. Since most of them did not fit the
normal distribution, we used Wilcoxon signed-rank test
(paired samples) to study modifications induced over
time by tDCS within the same subjects, and we employed
Whitney–Mann U-test to compare electrophysiological
values between HV and MoA groups. The time-dependent
changes in habituation were assessed with one-way analysis
of variance (ANOVA) for repeated measures. We also did
a post-hoc comparison with Wilcoxon signed-rank test. All
results were considered significant at p < 0.05.
Results
Electrophysiological study
The results of the electrophysiological study are presented
in Table 1 and Figure 2.
In baseline (T0), HV and MoA did not differ in first
PR-VEP block amplitude, nor in N1P1 habituation slopes
(p > 0.05). However, P1N2 habituation slope was signifi-
cantly deeper in HV than in MoA (−0.23 in HV vs. -0.05
in MoA; p = 0.04), which mirrors a lack of habituation in
MoA compared to HV.
In the HV group, anodal tDCS stimulation had no effect
on PR-VEP first block amplitude (N1P1: 6.1 μV ±2.0 at T0
vs. 6.8 μV ±2.6 at T1; p = 0.45; P1N2: 6.6 μV ±2.1 at T0 vs.
6.5 μV ±2.0 at T1; p = 0.49), and did not modify the ampli-
tude of subsequent blocks (Table 1). However, the habitu-
ation slope of N1P1 amplitude became more negative
after tDCS stimulation, i.e. tDCS was able to strengthen
habituation in HV at T1 (p = 0.024, Figure 2 Panel A) but
this change in habituation did not persist after 3 hours
(T2) where it returned on average to baseline values.
In the MoA group, anodal tDCS did not induce any
significant effect on VEP amplitudes as well (Table 1).
However, like in HV, N1P1 and P1N2 habituations in-
creased immediately after anodal tDCS (T1), and for
N1P1 slope this change was significant ( −0.11 to −0.24Table 1 This table shows the results of the electrophysiologic
and P1N2, μV), and habituation slopes in healthy volunteers
and 3 h after anodal tDCS










The * mark corresponds to a significant change (p < 0.05).after tDCS, p = 0.04, Figure 2 Panel C), meaning that
tDCS was also able to increase the habituation level in
MoA. These changes did not last for a long time and
returned to baseline at T2 as well.
Therapeutic study
The results of the pilot therapeutic study with anodal tDCS
in MoA are presented in Figure 3 and are encouraging.
Hence, during the 8 weeks of anodal tDCS treatment,
there was already on average a significant reduction of
migraine frequency, which was decreased from 9.6 days
in 2 months to 6.3 (34%,p = 0.005), while there was a re-
markable reduction in the number of migraine days from
15 to 8 (47%, p = 0.01). The average cumulative attack
duration over 2 months decreased from 184 to 119 hours
(35%, p = 0.043), and the average acute treatment intake
dropped from 18 tablets to 13 in two months (p = 0.041).
The duration of each attack slightly decreased as well, but
in a non-significant manner (p = 0.70).
We performed a further subanalysis where we only
considered the outcome within the last 4 weeks of tDCS,
which was compared to the baseline diary of the month
preceding tDCS application, on the assumption that the
clinical effect would improve with the repetition of tDCS
sessions. Migraine frequency reduction was more pro-
nounced during the second month of therapy, with a
mean decrease from 5 to 3 attacks (−38%; p = 0.03),
the number of migraine days also decreased from 8
to 4.3 (48%, p = 0.002), and noteworthy the average
attack duration dropped from 88.5 to 33.2 (60%, p = 0.02).
The drug intake tended to decrease from 9 pills/month to
6 pills/month (28%, p = 0.06).
To rule out a pure long-term pharmacological effect of
the ongoing preventive therapy we then compared
patients with (N = 5) and without (N = 5) migraine
preventive treatment. The evolution under tDCS treat-
ment was similar in both groups: patients without drugal study: Pattern Reversal-VEP initial amplitudes (N1P1
(HV) and episodic migraineurs (MoA), before, just after
) Habituation slope (over six blocks)
+ 3h Before After + 3h
6.3±2.2 -0.07±0.14 -0.21±0.14* -0.08±0.14
6.0±1.6 -0.18±0.19 -0.14±0.16 -0.12±0.25
7.2±2.7 -0.10±0.11 -0.24±0.18* -0.11±0.17
6.8±2.5 -0.01±0.21 -0.17±0.24 -0.07±0.21
Figure 2 Time-dependent changes of habituation slope after anodal tDCS. From the up to the bottom of the table the changes on
habituation slopes induced by anodal tDCS on N1P1 and P1N2 in healthy volunteers (HV, Panel A and Panel B) and episodic migraine patients
(MoA, Panel C and Panel D) at T0, T1 and T2. The habituation value is expressed as the decrement of the response with stimulus repetition so a
more negative value of the slope corresponds to a stronger habituation. The value of the slope at T0, T1, T2 was reported at every time point as
it is obtained by the interpolation of mean values in all blocks by linear regression equation. The x axis corresponds to the time (T0 = baseline;
T1 = immediately after the stimulation; T2 = after 3 hours).
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± 2.19 attacks in two months (p = 0.04), while in patients
under preventive therapy the frequency decreased from
10 ± 1.4 to 7.2 ± 1.8 attacks in two months (p = 0.04). No
inter-group difference was found (p = 0.45). In addition,
when we compared the sustained post-treatment be-
nefit, we found no difference between the 2 groups in
terms of attack recurrence: the group without any
drug preventive therapy returned to the baseline migraine
frequency 4.2 ± 3.8 weeks after the end of tDCS, while the
group under prophylaxis returned to baseline migraine
frequency after 5.4 ± 3.7 weeks (p = 0.62). Hence, a delayed
effect due to the drug preventive treatment seems unlikely.Adverse events
No adverse events were reported by patients, neither in
the electrophysiological nor in the therapeutical tDCS
study, but a light itching sensation that invariantly
disappeared in few minutes after the end of stimulation.Discussion
As we said before, the lack of cortical habituation to
repetitive sensory stimuli is the more reproducible elec-
trophysiological hallmark of the migrainous brain when
recordings are made interictally. As far as we know, this
is the first study using excitatory tDCS in order to modify
habituation, especially to normalize it in migraineurs, andtrying afterwards to translate these findings into a new
kind of preventive therapy.
Electrophysiological study
The results of our electrophysiological study are in line
with those found previously with rTMS, where an exci-
tatory 10 Hz stimulation was able to increase the initial
lower VEP response and restore normal habituation in
migraineurs [12]. The latter supported the idea that
the habituation deficit could be due to a lower
preactivation level of the brain cortex, and suggested
that transcutaneous central neurostimulation could
have therapeutic potentials in migraine.
We chose to perform anodal, i.e. “excitatory” tDCS
along the same line, in order to increase visual cortex
preactivation and subsequently correct the lack of
habituation in migraineurs. However we did not find any
enhancement of the VEP initial amplitude, neither in
healthy subjects nor in migraineurs, but surprisingly
tDCS increased habituation of the second component of
the VEP in both groups. Like in the rTMS [12] the
duration of tDCS effect on habituation was brief and VEP
recordings performed after 3 hours (T2) demonstrated that
habituation slopes had come back to baseline values. The
significant increase of habituation in absence of any initial
amplitude modification, i.e. any cortical preactivation level
enhancement with tDCS, is difficult to explain. It could be
attributed to the different mechanisms of action of tDCS
p=0.005 
PANEL F AVERAGE DURATION OF EACH
ATTACK
PANEL E DRUGS INTAKE
PANEL D MEAN PAIN INTENSITYPANEL C DURATION OF MIGRAINE ATTACKS
PANEL B DAYS OF MIGRAINEPANEL A MIGRAINE ATTACK FREQUENCY
Figure 3 This figure shows the outcome of the therapeutic pilot trial. The averages and standard deviations (black lines) of the following
clinical parameters are displayed at baseline and for the whole period of tDCS treatment: migraine frequency (Panel A), days with migraine (Panel B),
cumulated duration of all headache attacks (Panel C), pain intensity per attack (Panel D), acute drug intake (Panel E) and duration of each single
attack (Panel F).
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cortical dysexcitability found in migraine could also be
related to abnormal inhibitory circuits within the cortex,
and that an impaired habituation does not necessary
requires a lower preactivation level [35].
The relationship between the electrophysiological
abnormalities and the patient clinical state is still obscure
and complex; and whether the normalization of electro-
physiological responses with neuromodulation could lead
to a concomitant significant clinical improvement in
migraineurs remains debated. Hence, we had shown a
while ago that effective prophylaxis with betablockers was
correlated to an average normalization of auditory evoked
potentials (AEP), but not effective riboflavine therapy,
which did not modify AEP, suggesting 2 distinct mecha-
nisms [36]. In another study we had found similar electro-
physiological abnormalities in healthy volunteers with afamilial history of migraine, although they did not have
any headache themselves at the time of the recordings
[37]. A recent publication found that topiramate [38], one
of the most effective drugs in migraine prevention, was
able to normalize habituation in these patients. At baseline,
episodic migraineurs showed a significant lack of habitu-
ation, which disappeared after 2 months of treatment with
topiramate, and the individual improvement of habituation
was positively correlated with the clinical benefit.
This underlined the need for a proof-of-concept clinical
trial using a central neuromodulation technique able to
normalize habituation, such as anodal tDCS.
Therapeutic study
The results of our pilot trial with anodal tDCS in only
10 MoA patients are encouraging and most clinical vari-
ables already significantly improved within 8 weeks of
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intake and attack duration decreased, and this improve-
ment was even stronger in the second month of treat-
ment (except for acute medications), which underlines
that anodal tDCS preventive therapy sessions should
be continued on a regular basis for at least 2 months,
like drug prophylaxis or other non-invasive neurosti-
mulation techniques, for example supraorbital nerve stimu-
lation [39]. Migraine days and attack duration exhibited the
strongest average improvement with respectively 48% and
60% reduction. However, we are aware that our study has
some shortcomings. A placebo effect cannot be ruled out
without a randomized controlled trial. Moreover, some pa-
tients might have a long-term response to drug prophylaxis,
but the comparison between treated and untreated patients
could argue against this hypothesis (both responded simi-
larly to tDCS), as well as the attack recurrence observed in
most patients after the end of tDCS, within a variable time
interval. Finally, the improvement of patients under
long-term tDCS therapy contrasts with the results of
the electrophysiological study, where one single tDCS
session over the visual cortex only induced a very
short-term habituation modification (<3 h). However,
the repetition of tDCS sessions over 8 weeks could
have been responsible for neuroplastic changes and
induce sustained modifications within the underlying
visual cortex. Unfortunately, we did not record VEPs
before and after the 8 weeks of tDCS therapy. These
measures could be worthwhile in a next study.
In a pathophysiological point of view, these results
emphasize that the lack of habituation is probably playing
a key role in the genesis of migraine headache, even if
other pathological mechanisms may also be involved.
There are few existing trials on migraine prevention
using central non-invasive neurostimulation methods, i.e.
rTMS or tDCS, and their stimulation paradigms differed
according to the author’s baseline pathophysiological
hypotheses. Thus, in order to correct an eventual cortical
hyperexcitability, Teepker et al. [30] and Antal et al. [31]
applied inhibitory stimulations, respectively 1Hz-rTMS
and cathodal tDCS over the vertex and the visual cortex,
leading to minor or negative clinical results. This could
eventually be due to an incorrect baseline assumption.
Chronic migraine management is often challenging and
thus non-invasive neurostimulation could offer a new hope
to these patients. The patients included in our clinical
study did not fulfill the criteria for chronic migraine, and
we stress that excitatory stimulations paradigms could even
be counterproductive in these patients. Even if the excita-
tory 10 Hz-stimulation of the dorsolateral prefrontal cortex
(DLPFC), known for its implication in pain control [40],
was able to slightly improve chronic migraine patients [29],
these results were also uncontrolled and there was a
comorbid state of depression which might have been amajor confounding factor. Hence, beyond depression,
chronic migraine seems to differ from episodic migraine in
terms of brain excitability. While habituation deficit is a
hallmark of the disease in episodic migraine, in
chronic migraine, surprisingly, habituation does not
differ from control subjects [19]. Recent works suggest that
in chronic migraine, the cerebral cortical excitability
increases as the activity of cortical inhibitory interneurons
decreases, which finally leads to a normal habituation, at
least in visual areas (for details, see [41]). When the same
chronic patients are successfully treated and evolve to
episodic migraine, the lack of habituation reappears. These
data support the idea that chronic migraine could be a
“never-ending attack [20,21]. Thus, we believe that chronic
migraine should paradoxically be treated using inhibitory
stimulations unlike episodic migraine and that excitatory
stimulations, like anodal tDCS reported in the present
study, could be ineffective or even worsen these patients.
More neurostimulation studies are warranted to confirm
this assumption.
Conclusion
This study demonstrates for the first time that a 15-min
session of anodal tDCS over the visual cortex is able to
transiently increase habituation in healthy volunteers but
also in episodic migraineurs. Its mechanism of action
does not seem to involve cortical preactivation modifica-
tions as the initial amplitude of the visual evoked potentials
is not modified.
The same excitatory paradigm applied twice a week
during 8 weeks as preventive therapy in 10 episodic
migraineurs results in a significant reduction of migraine
attack frequency, migraine days, painkiller intake and
attack duration. All positive effects seem to improve with
time, suggesting that preventive therapy with anodal tDCS
should be performed on a regular basis, and could involve
additional slow neuromodulating processes.
These encouraging results need to be confirmed in a
well-designed randomized controlled trial.
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